LianBio
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which … Read more
LianBio (LIANY) - Total Liabilities
Latest total liabilities as of December 2023: $36.77 Million USD
Based on the latest financial reports, LianBio (LIANY) has total liabilities worth $36.77 Million USD as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LianBio - Total Liabilities Trend (2019–2024)
This chart illustrates how LianBio's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LianBio Competitors by Total Liabilities
The table below lists competitors of LianBio ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rocky Mountain Chocolate Factory
NASDAQ:RMCF
|
USA | $14.72 Million |
|
Wellysun Inc
TW:6988
|
Taiwan | NT$465.80 Million |
|
Radhika Jeweltech Limited
NSE:RADHIKAJWE
|
India | ₹823.02 Million |
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
USA | $5.06 Million |
|
Icape Holding
PA:ALICA
|
France | €132.84 Million |
|
Eden Research plc
PINK:EDNSF
|
USA | $2.85 Million |
|
Goa Carbon Limited
NSE:GOACARBON
|
India | ₹4.22 Billion |
|
OCR Group Bhd
KLSE:7071
|
Malaysia | RM419.46 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down LianBio's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LianBio's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LianBio (2019–2024)
The table below shows the annual total liabilities of LianBio from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | $859.00K | -97.66% |
| 2023-09-30 | $36.77 Million | +39.73% |
| 2022-09-30 | $26.31 Million | -32.54% |
| 2021-09-30 | $39.01 Million | +41.50% |
| 2020-09-30 | $27.57 Million | +646.07% |
| 2019-09-30 | $3.69 Million | -- |